Lv2
140 积分 2024-12-06 加入
Anti-IL17 treatment in childhood chronic rheumatic diseases
1天前
待确认
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies
1个月前
已完结
The Role of IL-17 in Systemic Autoinflammatory Diseases: Mechanisms and Therapeutic Perspectives
2个月前
已完结
The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis
4个月前
已完结
A strategy towards disentangling treatment refractory from misdiagnosed axial Spondyloarthritis
4个月前
已完结
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
7个月前
已完结
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
7个月前
已完结
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
7个月前
已完结
皖公网安备34019202002308
